Lana Pine

S Louis Bridges Jr, MD, PhD, explores the role of artificial intelligence in managing rheumatoid arthritis.

Benjamin Smith, DMSc, PA-C, discusses integrative rheumatoid arthritis treatment guidelines.

Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.

Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.

Without controlling for the severity of symptoms, patients with either fibromyalgia or RA performed worse when compared with controls in terms of cognitive domains including verbal memory, visual memory, and strategic planning.

Alkaline water significantly reduced VAS pain scores among patients with gout.

Five barriers to adopting TNF therapeutic drug monitoring emerged among a cohort of experienced rheumatologists.

For those with a family history of gout, the proportion of grade ≥ 2 left ventricular diastolic insufficiency was markedly higher compared with patients without family history.

The median survival for triple therapy was longer compared with double therapy (15.1 months vs 9.6 months).

Obesity was linked to a lower likelihood of obtaining response to treatment during the 48-week follow-up period.

Patients with gout who had poor health literacy were more likely to experience ≥ 2 flares within the previous 12 months.

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA.

Katie Abouzahr, MD, explains the transformative potential of nipocalimab for the treatment of patients with autoantibody-driven conditions.

Patients with higher disease activity reported the highest perceived consequence of disease.

Clinicians advocate for an at-parity approach to biosimilars, in which they, their patients, and the local market would have the freedom to choose the product that best suits their needs.

Manuel Litchman, MD, further discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

Manuel Litchman, MD, discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

In March, FDA approved biosimilar versions of established biologic drugs for autoimmune diseases and skeletal-related events, adalimumab biosimilars demonstrated sustained efficacy and acceptance among patients, and affirmed CT-P41’s potential as an alternative treatment options in clinical practice.

This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.

Exercise was beneficial in functional status for both patients with RA and spondyloarthritis.

Results offer important guidance for healthcare providers to develop tailored treatment strategies that align with the unique needs and preferences of individual patients.

Birthweight was significantly lower in women who were not treated with a TNF.

Gut microbiota-based treatment relieved pain for patients with fibromyalgia.

Kenneth Saag, MD, explores the clinical significance of a study demonstrating treatment with pegloticase leads to bone remodeling in patients with gout.

At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.

Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.

Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.

Compared with RA, patients with PsA had a higher diagnostic delay and a greater time between the onset of symptoms and the start of treatment.

Receiving methotrexate and leflunomide within the 3 months prior to conception was linked to an increased rate of adverse pregnancy outcomes.

Between 2009 and 2020, the number of rheumatologists increased 23%, from 4557 to 5600.